KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Operating Expenses: 2017-2025

Historic Operating Expenses for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to $24.3 million.

  • Aquestive Therapeutics' Operating Expenses rose 11.24% to $24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.2 million, marking a year-over-year increase of 23.98%. This contributed to the annual value of $88.3 million for FY2024, which is 34.48% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Operating Expenses stood at $24.3 million for Q3 2025, which was up 13.64% from $21.4 million recorded in Q2 2025.
  • Aquestive Therapeutics' Operating Expenses' 5-year high stood at $28.1 million during Q1 2025, with a 5-year trough of $15.4 million in Q3 2023.
  • For the 3-year period, Aquestive Therapeutics' Operating Expenses averaged around $20.7 million, with its median value being $21.0 million (2024).
  • Per our database at Business Quant, Aquestive Therapeutics' Operating Expenses crashed by 32.95% in 2023 and then surged by 48.66% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Operating Expenses (Quarterly) stood at $22.7 million in 2021, then decreased by 5.94% to $21.4 million in 2022, then declined by 20.00% to $17.1 million in 2023, then surged by 48.66% to $25.4 million in 2024, then grew by 11.24% to $24.3 million in 2025.
  • Its Operating Expenses was $24.3 million in Q3 2025, compared to $21.4 million in Q2 2025 and $28.1 million in Q1 2025.